FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jasper, J. R.
Right arrow Articles by Insel, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jasper, J. R.
Right arrow Articles by Insel, P. A.

The FASEB Journal, Vol 2, 2891-2894, Copyright © 1988 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Molecular mechanism of beta-adrenergic receptor blockers with intrinsic sympathomimetic activity

JR Jasper, MC Michel and PA Insel
Department of Pharmacology, University of California, San Diego, La Jolla 92093.

beta-Adrenergic receptor (beta AR) blocking agents with intrinsic sympathomimetic activity (ISA) can induce modest increases in beta AR- stimulated activity, such as rate and force of contraction in cardiac tissue. The molecular basis for this activity has been elusive. Previous studies have suggested that these compounds do not stimulate cyclic AMP (cAMP) formation even though activation of adenylate cyclase is the generally accepted mechanism for beta AR promotion of target cell response. In the current studies, we show that several beta AR antagonists with ISA (dichloroisoproterenol, pindolol, and celiprolol) stimulate cAMP accumulation five-, two-, and threefold, respectively, in S49 lymphoma cells, but only if cells are simultaneously incubated with the diterpene forskolin. The KI values observed for inhibition of isoproterenol-stimulated cAMP accumulation or of beta AR [( 125I]iodocyanopindolol) binding for each of the beta blockers with ISA were comparable in magnitude to their respective EC50 values for forskolin-potentiated cAMP accumulation. The forskolin-potentiated responses of these compounds were abolished by the beta AR-antagonist propranolol. These results indicate that the ISA of beta-blocking drugs most likely results from a modest beta AR-mediated stimulation of adenylate cyclase activity. The results further suggest that treatment of target cells with forskolin provides a means to define partial agonism at receptors that are linked to stimulation of adenylate cyclase.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
N. Azzam, R. Bar-Shalom, Z. Kraiem, and F. Fares
Human Thyrotropin (TSH) Variants Designed by Site-Directed Mutagenesis Block TSH Activity in Vitro and in Vivo
Endocrinology, June 1, 2005; 146(6): 2845 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Bundkirchen, K. Brixius, B. Bolck, and R. H. G. Schwinger
Bucindolol Exerts Agonistic Activity on the Propranolol-Insensitive State of beta 1-Adrenoceptors in Human Myocardium
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 794 - 801.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Torres, A. C. Zambon, and P. A. Insel
P2Y11 Receptors Activate Adenylyl Cyclase and Contribute to Nucleotide-promoted cAMP Formation in MDCK-D1 Cells. A MECHANISM FOR NUCLEOTIDE-MEDIATED AUTOCRINE-PARACRINE REGULATION
J. Biol. Chem., March 1, 2002; 277(10): 7761 - 7765.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by The Federation of American Societies for Experimental Biology.